Abstract Number: VPB0942
Meeting: ISTH 2022 Congress
Theme: Venous Thromboembolism » Cancer Associated Thrombosis
Background: Papillary thyroid cancer (PTC) and its variants (classical (CV), tall cell (TCV) and follicular variant (FV)) accounts for approximately 80% of all thyroid cancers. Mutations of the RET and BRAF(V600) genes are found in nearly 70% of PTC cases. They are able to trigger the activation of mitogen-activated protein kinase pathway and to promote neoplastic cell proliferation and possible hypercoagulability. The number of studies on venous thromboembolism (VTE) and pulmonary embolism (PE) coexist with PTC is limited and medical data are contradictory.
Aims: The aim of the study was to perform the genomyc analysis of the RET and BRAF(V600) mutations in patients with PTC and to determine the prevalence and risk factors associated with VTE and PE taking into consideration the status of RET and BRAF(V600) genotype.
Methods: The study included 112 patients, aged 49-74 years. Mutations of the RET and BRAF(V600) genes were detected using Real-time polymerase chain reaction. Diagnosis of the PTC and its variants were confirmed with cyto/histopathological examination. Diagnostic strategies were evaluated for VTE and PE.
Results: The most important genomic, cyto/histopathological and prognostic elements regarding all three variants of the PTC: CV-PTC (n=78): RET and BRAF(V600) mutations are common findings, with BRAF(V600) confirming a worse prognosis. The 65% of these patients have shown stabile disease course, with 25% with metastatic nodes; TCV-PTC (n=8): Aggressive behavior has been attributed to BRAF(V600) mutation. FV-PTC (n=26): Absence of BRAF(V600) mutation was the most important genetic element. Although some studies have shown a possible increase in VTE and PE occurrence in PTC patients harbouring RET and BRAF(V600) mutation, our studie could not confirm these data.
Conclusion(s): The presence of RET and BRAF(V600) mutation status and increased risk of VTE and PE in patients with PTC could not be confirmed
To cite this abstract in AMA style:
Katalinic D, Aleric I, Vcev A, Solter M, Toetome L. Association between RET and BRAF(V600) oncogenic status and risk of venous and pulmonary thromboembolism in patients with papillary thyroid cancer [abstract]. https://abstracts.isth.org/abstract/association-between-ret-and-brafv600-oncogenic-status-and-risk-of-venous-and-pulmonary-thromboembolism-in-patients-with-papillary-thyroid-cancer/. Accessed March 21, 2024.« Back to ISTH 2022 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/association-between-ret-and-brafv600-oncogenic-status-and-risk-of-venous-and-pulmonary-thromboembolism-in-patients-with-papillary-thyroid-cancer/